@article{468db8e29d63435589b9c109c3d3b1a2,
title = "Vertebrate Fidgetin Restrains Axonal Growth by Severing Labile Domains of Microtubules",
abstract = "Individual microtubules (MTs) in the axon consist of a stable domain that is highly acetylated and a labile domain that is not. Traditional MT-severing proteins preferentially cut the MT in the stable domain. In Drosophila, fidgetin behaves in this fashion, with targeted knockdown resulting in neurons with a higher fraction of acetylated (stable) MT mass in their axons. Conversely, in a fidgetin knockout mouse, the fraction of MT mass that is acetylated is lower than in the control animal. When fidgetin is depleted from cultured rodent neurons, there is a 62% increase in axonal MT mass, all of which is labile. Concomitantly, there are more minor processes and a longer axon. Together with experimental data showing that vertebrate fidgetin targets unacetylated tubulin, these results indicate that vertebrate fidgetin (unlike its fly ortholog) regulates neuronal development by tamping back the expansion of the labile domains of MTs.",
author = "Lanfranco Leo and Wenqian Yu and Mitchell D'Rozario and Waddell, {Edward A.} and Marenda, {Daniel R.} and Baird, {Michelle A.} and Davidson, {Michael W.} and Bin Zhou and Bingro Wu and Lisa Baker and Sharp, {David J.} and Baas, {Peter W.}",
note = "Funding Information: This work was funded by a grant from the Craig H. Neilsen Foundation (259350) to P.W.B., a grant to D.J.S. from the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) through award W81XWH1210379, a grant from the National Science Foundation (IOS1256114) to D.R.M., and grants from the NIH to P.W.B. (R01 NS28785) and D.J.S. (R01 GM109909). L.L. is supported by Drexel Dean{\textquoteright}s Fellowship for Excellence in Collaborative Research Training. The authors are appreciative to Dr. B. Timothy Himes for assistance with tissue preparation and Dr. Vladimir Zhukarev for assistance with microscopy. D.J.S. is Chief Scientific Officer and P.W.B. and B.Z. are members of the Scientific Board of Microcures, a biotechnology company that has identified Fgn as a potential target for therapeutic applications. Publisher Copyright: {\textcopyright} 2015 The Authors.",
year = "2015",
month = sep,
day = "22",
doi = "10.1016/j.celrep.2015.08.017",
language = "English (US)",
volume = "12",
pages = "1723--1730",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "11",
}